NEW YORK, NY / ACCESSWIRE / December 10, 2018 / U.S. stocks closed in the red on Friday as U.S. jobs report fell short of expectations and uncertainty over the U.S. -China trade talk spur markets lower. The Dow Jones Industrial Average fell 2.24 percent to close at 24,388.95, while the S&P 500 Index decreased 2.33 percent to close at 2,633.08. The Nasdaq Composite Index dropped 3.05 percent to close at 6,969.25. The U.S. Labor Department reported an increase of 155,000 jobs in November, compared to 190,000 increase forecasted economists polled by MarketWatch. For the week, the Dow Jones shed 4.5 percent, while the S&P 500 and Nasdaq declined 4.6 percent and 4.9 percent, respectively.
The Market Edge Initiates Coverage on:
Tesaro's stock moved 0.23% higher Friday, to close the day at $73.95. The stock recorded a trading volume of 5,081,330 shares, which was above its three months average volume of 3,162,017 shares. In the last year, Tesaro's shares have traded in a range of 23.41 - 85.00. The share price has gained 215.89% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $40.38 is above its 200-day moving average of $39.03. Shares of Tesaro have gained roughly 194.62 percent in the past month and are down 10.76 percent year-to-date.
Access The Market Edge's Tesaro, Inc. Research Report:
On Friday, shares of Celgene recorded a trading volume of 6,592,195 shares, which was above the three months average volume of 5,762,137 shares. The stock ended the day 3.74% lower at $70.08. The share price has fallen 36.76% from its 52 week high with a 52 week trading range of 66.62 - 110.81. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $72.15 is below its 200-day moving average of $82.19. Shares of the company are trading at a Price to Earnings ratio of 18.25. Shares of Celgene have fallen roughly 5.32 percent in the past month and are down 32.85 percent year-to-date.
Access The Market Edge's Celgene Corporation Research Report:
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.